Autolus Interest Income vs Research Development Analysis

AUTL Stock

USD 3.27 0.17 5.48%

Autolus Therapeutics financial indicator trend analysis is way more than just evaluating Autolus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Autolus Therapeutics is a good investment. Please check the relationship between Autolus Therapeutics Interest Income and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

Interest Income vs Research Development

Interest Income vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Autolus Therapeutics Interest Income account and Research Development. At this time, the significance of the direction appears to have weak relationship.

The correlation between Autolus Therapeutics' Interest Income and Research Development is 0.39. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Research Development in the same time period over historical financial statements of Autolus Therapeutics, assuming nothing else is changed. The correlation between historical values of Autolus Therapeutics' Interest Income and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of Autolus Therapeutics are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Interest Income i.e., Autolus Therapeutics' Interest Income and Research Development go up and down completely randomly.

Correlation Coefficient

0.39

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Research Development

Most indicators from Autolus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Autolus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.At this time, Autolus Therapeutics' Sales General And Administrative To Revenue is quite stable compared to the past year. Enterprise Value is expected to rise to about 882.2 M this year, although the value of Selling General Administrative will most likely fall to about 25.9 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	8.5M	7.4M	6.6M	4.5M
Interest Income	262K	1.7M	11.9M	12.5M

Depreciation And Amortization Interest Income

Autolus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Other Current Assets	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity
Total Assets		0.76	0.91	0.8	0.86	-0.65	-0.22	0.95	0.09	0.77	0.65	0.98	-0.71	0.7	0.77	0.58	0.68	0.65	-0.71	0.73	0.21	0.83	0.57	0.6	0.78	0.85
Other Current Liab	0.76		0.8	0.42	0.61	-0.77	-0.28	0.68	-0.22	0.88	0.86	0.7	-0.64	0.89	0.64	0.72	0.83	0.77	-0.49	0.71	0.15	0.63	0.82	0.84	0.54	0.76
Total Current Liabilities	0.91	0.8		0.52	0.69	-0.8	-0.43	0.77	0.14	0.82	0.79	0.82	-0.83	0.8	0.9	0.78	0.82	0.82	-0.52	0.91	0.23	0.71	0.7	0.74	0.8	0.94
Total Stockholder Equity	0.8	0.42	0.52		0.78	-0.18	0.16	0.86	0.25	0.38	0.19	0.86	-0.37	0.26	0.46	0.19	0.22	0.26	-0.66	0.31	0.17	0.68	0.12	0.13	0.55	0.41
Net Tangible Assets	0.86	0.61	0.69	0.78		-0.32	0.22	0.88	0.08	0.47	0.43	0.87	-0.36	0.48	0.53	0.34	0.42	0.4	-0.59	0.51	-0.13	0.66	0.42	0.39	0.71	0.55
Retained Earnings	-0.65	-0.77	-0.8	-0.18	-0.32		0.79	-0.48	0.1	-0.92	-0.94	-0.54	0.91	-0.92	-0.74	-0.88	-0.95	-0.92	0.33	-0.81	-0.36	-0.53	-0.89	-0.93	-0.5	-0.91
Accounts Payable	-0.22	-0.28	-0.43	0.16	0.22	0.79		-0.03	0.0	-0.59	-0.56	-0.11	0.78	-0.52	-0.49	-0.62	-0.62	-0.63	0.04	-0.54	-0.58	-0.19	-0.49	-0.57	-0.16	-0.66
Cash	0.95	0.68	0.77	0.86	0.88	-0.48	-0.03		-0.07	0.68	0.52	0.99	-0.51	0.6	0.55	0.34	0.54	0.43	-0.81	0.49	0.11	0.86	0.45	0.48	0.66	0.7
Net Receivables	0.09	-0.22	0.14	0.25	0.08	0.1	0.0	-0.07		-0.32	-0.2	0.0	-0.23	-0.24	0.45	0.26	-0.13	0.2	0.32	0.32	0.17	-0.21	-0.25	-0.25	0.3	-0.01
Other Current Assets	0.77	0.88	0.82	0.38	0.47	-0.92	-0.59	0.68	-0.32		0.89	0.71	-0.8	0.91	0.66	0.72	0.89	0.79	-0.58	0.71	0.32	0.72	0.83	0.88	0.52	0.91
Total Liab	0.65	0.86	0.79	0.19	0.43	-0.94	-0.56	0.52	-0.2	0.89		0.56	-0.78	0.99	0.64	0.85	0.99	0.89	-0.37	0.74	0.13	0.54	0.98	1.0	0.48	0.82
Total Current Assets	0.98	0.7	0.82	0.86	0.87	-0.54	-0.11	0.99	0.0	0.71	0.56		-0.59	0.63	0.64	0.43	0.59	0.51	-0.79	0.58	0.16	0.86	0.48	0.52	0.7	0.76
Intangible Assets	-0.71	-0.64	-0.83	-0.37	-0.36	0.91	0.78	-0.51	-0.23	-0.8	-0.78	-0.59		-0.76	-0.87	-0.88	-0.83	-0.91	0.37	-0.88	-0.43	-0.58	-0.71	-0.75	-0.67	-0.91
Common Stock	0.7	0.89	0.8	0.26	0.48	-0.92	-0.52	0.6	-0.24	0.91	0.99	0.63	-0.76		0.63	0.81	0.98	0.85	-0.45	0.72	0.13	0.6	0.96	0.99	0.49	0.83
Property Plant Equipment	0.77	0.64	0.9	0.46	0.53	-0.74	-0.49	0.55	0.45	0.66	0.64	0.64	-0.87	0.63		0.85	0.67	0.87	-0.25	0.97	0.4	0.48	0.55	0.59	0.77	0.85
Short Long Term Debt Total	0.58	0.72	0.78	0.19	0.34	-0.88	-0.62	0.34	0.26	0.72	0.85	0.43	-0.88	0.81	0.85		0.86	0.99	-0.09	0.9	0.31	0.32	0.82	0.83	0.57	0.77
Other Liab	0.68	0.83	0.82	0.22	0.42	-0.95	-0.62	0.54	-0.13	0.89	0.99	0.59	-0.83	0.98	0.67	0.86		0.89	-0.4	0.76	0.16	0.57	0.95	0.98	0.51	0.85
Property Plant And Equipment Net	0.65	0.77	0.82	0.26	0.4	-0.92	-0.63	0.43	0.2	0.79	0.89	0.51	-0.91	0.85	0.87	0.99	0.89		-0.2	0.92	0.3	0.43	0.85	0.87	0.62	0.83
Net Debt	-0.71	-0.49	-0.52	-0.66	-0.59	0.33	0.04	-0.81	0.32	-0.58	-0.37	-0.79	0.37	-0.45	-0.25	-0.09	-0.4	-0.2		-0.26	0.08	-0.97	-0.34	-0.34	-0.6	-0.53
Non Current Assets Total	0.73	0.71	0.91	0.31	0.51	-0.81	-0.54	0.49	0.32	0.71	0.74	0.58	-0.88	0.72	0.97	0.9	0.76	0.92	-0.26		0.28	0.49	0.69	0.71	0.8	0.88
Non Currrent Assets Other	0.21	0.15	0.23	0.17	-0.13	-0.36	-0.58	0.11	0.17	0.32	0.13	0.16	-0.43	0.13	0.4	0.31	0.16	0.3	0.08	0.28		0.01	-0.01	0.11	-0.07	0.36
Cash And Short Term Investments	0.83	0.63	0.71	0.68	0.66	-0.53	-0.19	0.86	-0.21	0.72	0.54	0.86	-0.58	0.6	0.48	0.32	0.57	0.43	-0.97	0.49	0.01		0.49	0.51	0.74	0.71
Common Stock Shares Outstanding	0.57	0.82	0.7	0.12	0.42	-0.89	-0.49	0.45	-0.25	0.83	0.98	0.48	-0.71	0.96	0.55	0.82	0.95	0.85	-0.34	0.69	-0.01	0.49		0.98	0.47	0.74
Non Current Liabilities Total	0.6	0.84	0.74	0.13	0.39	-0.93	-0.57	0.48	-0.25	0.88	1.0	0.52	-0.75	0.99	0.59	0.83	0.98	0.87	-0.34	0.71	0.11	0.51	0.98		0.44	0.79
Capital Surpluse	0.78	0.54	0.8	0.55	0.71	-0.5	-0.16	0.66	0.3	0.52	0.48	0.7	-0.67	0.49	0.77	0.57	0.51	0.62	-0.6	0.8	-0.07	0.74	0.47	0.44		0.72
Other Stockholder Equity	0.85	0.76	0.94	0.41	0.55	-0.91	-0.66	0.7	-0.01	0.91	0.82	0.76	-0.91	0.83	0.85	0.77	0.85	0.83	-0.53	0.88	0.36	0.71	0.74	0.79	0.72

Click cells to compare fundamentals

Autolus Therapeutics Account Relationship Matchups

Autolus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	303.5M	294.2M	405.6M	490.3M	375.4M	275.2M
Other Current Liab	716K	24.2M	23.7M	35.8M	34.5M	36.3M
Total Current Liabilities	25.0M	33.6M	28.6M	46.4M	44.7M	23.4M
Total Stockholder Equity	254.8M	210.0M	313.3M	298.7M	111.5M	196.4M
Net Tangible Assets	254.6M	209.9M	313.3M	298.7M	343.5M	213.2M
Retained Earnings	(237.2M)	(379.2M)	(521.3M)	(670.2M)	(878.6M)	(834.6M)
Accounts Payable	1.1M	2.3M	431K	531K	103K	97.9K
Cash	210.6M	153.3M	310.3M	382.4M	239.6M	203.1M
Net Receivables	30.5M	29.7M	68K	153K	1.0M	994.6K
Other Current Assets	279K	14M	36.5M	43.2M	34.7M	36.4M
Total Liab	48.7M	84.2M	92.2M	191.6M	263.9M	277.1M
Total Current Assets	249.3M	197.0M	347.0M	425.8M	275.3M	228.1M
Common Stock	2K	3K	4K	8K	9.2K	9.7K
Property Plant Equipment	51.6M	89.7M	52.3M	58.4M	67.2M	36.1M
Short Long Term Debt Total	26.2M	54.2M	21.0M	24.3M	53.0M	55.6M
Other Liab	1.0M	492K	47.1M	126.0M	144.9M	152.2M
Property Plant And Equipment Net	51.6M	89.7M	52.3M	58.4M	95.7M	100.4M
Net Debt	(184.4M)	(99.1M)	(289.3M)	(358.2M)	(186.6M)	(195.9M)
Non Current Assets Total	54.3M	97.3M	58.6M	64.5M	100.1M	51.5M
Non Currrent Assets Other	2.0M	5.7M	4.4M	4.0M	1.4M	2.6M
Cash And Short Term Investments	210.6M	153.3M	310.3M	382.4M	239.6M	224.9M
Common Stock Shares Outstanding	43.1M	51.6M	72.1M	95.0M	173.9M	182.6M
Liabilities And Stockholders Equity	303.5M	294.2M	405.6M	490.3M	375.4M	304.0M
Non Current Liabilities Total	23.7M	50.6M	63.7M	145.2M	219.2M	230.1M
Other Stockholder Equity	500.7M	595.1M	843.2M	1.0B	1.0B	545.0M
Property Plant And Equipment Gross	51.6M	89.7M	75.0M	86.0M	124.4M	130.6M
Accumulated Other Comprehensive Income	(8.7M)	(5.9M)	(8.6M)	(38.9M)	(29.0M)	(30.4M)
Inventory	7.8M	(29.7M)	10.1M	14.2M	(23.5M)	(22.3M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:

How To Invest In Autolus

Details

Is Autolus Stock a good investment?

Details

What is Autolus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.22)

Revenue Per Share

0.043

Quarterly Revenue Growth

6.81

Return On Assets

(0.22)

Return On Equity

(0.82)

The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Autolus Interest Income vs Research Development Analysis

Interest Income vs Research Development

Interest Income vs Research Development Correlation Analysis

Correlation Coefficient

Interest Income

Research Development

Autolus Therapeutics fundamental ratios Correlations

Autolus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Autolus Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Total Current Assets	+ 0.99	Cash
Common Stock	+ 0.99	Total Liab
Other Liab	+ 0.99	Total Liab
Non Current Liabilities Total	+ 0.99	Common Stock
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total

Cash And Short Term Investments	- 0.97	Net Debt
Other Liab	- 0.95	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Non Current Liabilities Total	- 0.93	Retained Earnings
Property Plant And Equipment Net	- 0.92	Retained Earnings
Common Stock	- 0.92	Retained Earnings